ClinicalTrials.gg
TerminatedNCT04612725ARROYOUpdated Mar 13, 2024Results posted

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

A Phase 2 interventional study of Benralizumab and Placebo and Benralizumab in Chronic Spontaneous Urticaria, sponsored by AstraZeneca. Terminated at 40 sites in 7 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
Study did not meet primary endpoint

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
26th of 58
159 · median 132
Started
2020
with 2 others
Phase 2
23 of 64
4 open now
Registered
29th of 64
by date

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 26th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2020, is one of 23 in phase 2, and was the 29th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.

Read the detailed description

The aim of this study is to investigate the use of benralizumab as treatment for patients with chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines. It is proposed that benralizumab will deplete eosinophils and basophils from affected skin, improve symptoms of CSU, and improve CSU-related quality of life. This Phase 2b study is designed to evaluate induction and maintenance dosing regimens.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Keywords

  • chronic spontaneous urticaria,
  • skin lesion,
  • pruritus and wheals
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

/Age/Gender

  1. Provision of the signed and dated written informed consent of the participant prior to any mandatory study-specific procedures, sampling, and analyses.
  2. Adult participants≥18 years of age at the time of signing the Informed Consent Form (ICF).

    Type of Participants and Disease

  3. Physician-confirmed diagnosis of CSU (also known as chronic idiopathic urticaria) for at least 6 months prior to screening (Visit 1).
  4. Presence of pruritus and wheals for at least 6 consecutive weeks prior to screening (Visit 1), despite receiving standard of care, which may include second generation H1 antihistamines (at approved or up to 4-times approved doses) as monotherapy or in combination with LTRAs and/or H2 blockers.
  5. Symptomatic during run-in, defined by the following:

    1. UAS7 total score of ≥ 16 with an ISS7 of ≥ 8, during the 7 days prior to randomisation (Visit 2)
    2. In-clinic UAS total score of ≥ 4 on at least one of the screening days.
  6. Willing to use a second-generation H1 antihistamine at the approved dose and as monotherapy from the screening visit (Visit 1) until the end of the study.
  7. Participants must complete daily PRO assessments and meet the following compliance criteria:

    1. Complete at least 80% of daily PRO assessments between Visit 1 and Visit 2 and
    2. Complete at least 6 of 7 daily PRO assessments in the 7 days prior to Visit 2.
  8. Compliance with the locally-approved dose of antihistamine, maintained at randomisation.

    Reproduction

  9. Females of (FOCBP) must agree to use a highly effective method of (confirmed by the Investigator) from randomisation, throughout the study duration, and within12 weeks after last dose of IP and have a negative serum pregnancy test result on Visit 1. Highly effective methods of birth control include:

    1. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal.
    2. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable.
    3. Intrauterine device.
    4. Intrauterine hormone-releasing system.
    5. Bilateral tubal occlusion or ligation.
    6. Sexual abstinence, ie, refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant).
    7. Vasectomised sexual partner (provided that partner is the sole sexual partner of the FOCBP study participant and that the vasectomised partner has received medical assessment of the surgical success).
  10. Females not of childbearing potential are defined as Females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are . Females will be considered postmenopausal if they have been amenorrhoeic for≥12 months prior to the planned date of randomisation without an alternative medical cause. The following age-specific requirements apply:

    1. Females\<50 years old will be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone (FSH) levels in the postmenopausal range. Until FSH is documented to be within menopausal range, the participant should be treated as a FOCBP.
    2. Females≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. Participants with predominant inducible urticaria, ie, urticaria that is predominantly due to a clearly defined stimulus (eg, pressure [dermographism], delayed pressure, cold, heat, sunlight, vibration, water, physical exercise, or increased body temperature [cholinergic]).
  2. Participants with diseases, other than chronic urticaria, with urticaria or angioedema symptoms such as urticaria vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1-inhibitor deficiency). Additionally, any other skin disease associated with chronic itching and/or skin lesions that, in the investigators opinion, might influence the study evaluations and results (eg, atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).
  3. Current , or history of malignancy, with the exception of: (a) Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to the date , was obtained. (b) Participants who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to the date informed consent, was obtained.
  4. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: (a) Affect the safety of the participant throughout the study (b) Influence the findings of the studies or their interpretations (c) Impede the participant's ability to complete the entire duration of study.
  5. History of anaphylaxis to any biologic therapy or vaccine.
  6. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with,or has failed to respond to standard of care therapy.
  7. Any abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period which, in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete entire duration of the study.
  8. Current active liver disease:

    1. Chronic stable andC (including positive testing for hepatitis B surface antigen [HBsAg] or antibody), or other stable chronic liver disease are acceptable if participant otherwise meets eligibility criteria. Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice, or cirrhosis.
    2. (ALT) or aspartate aminotransferase (AST) level≥3 times the (ULN), confirmed by repeated testing during the run-in period. Transient increase of AST/ALT level that resolves by the time of randomisationis acceptable if in the Investigator's opinion the participant does not have an active liver disease and meets other eligibility criteria.
  9. A history of known immunodeficiency disorder including a positive (HIV) test. Prior/concomitant Therapy
  10. Use of medication, including, but not limited to: methotrexate, cyclosporine, azathioprine, topical and systemic within 4 weeks or 5 half-lives prior to the date informed consent is obtained, whichever is longer.
  11. Known history of allergy or reaction to any component of the IP formulation Other
  12. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
  13. Receipt of any marketed (eg, omalizumab) or biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer.
  14. Receipt of 30 days prior to the date of randomisation
  15. Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to the date informed consent is obtained, whichever is longer
  16. Previously received benralizumab (MEDI-563, FASENRA)
  17. Change to allergen immunotherapy or new allergen immunotherapy within 30 days prior to the date of informed consent and anticipated changes in immunotherapy throughout the study
  18. Planned elective major surgical procedures during the conduct of the study
  19. Previous randomization in the present study
  20. Concurrent enrollment in another clinical trial
  21. AstraZeneca staff involved in the planning and/or conduct of the study
  22. For Females only: Currently pregnant, breastfeeding, or lactating Females (a) A serum pregnancy test will be done for FOCBP at Visit 1 and a urine pregnancy test must be performed for FOCBP at each treatment visit prior to IP administration. A positive urine test result must be confirmed with a serum pregnancy test. If serum test is positive, the participant should be excluded.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Benralizumab Arm 1

    Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)

    Biological: Benralizumab

  • Experimental
    Benralizumab Arm 2

    Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)

    Biological: Benralizumab

  • Experimental
    Benralizumab Arm 3

    Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)

    Biological: Benralizumab

  • Experimental
    Benralizumab Arm 4

    Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)

    Biological: Benralizumab

  • Experimental
    Placebo and Benralizumab

    Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).

    Biological: Placebo and Benralizumab

Interventions

  • BiologicalBenralizumab

    2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.

    Also known as: Benralizumab, Benra, Fasenra

  • BiologicalPlacebo and Benralizumab

    2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.

    Also known as: Benralizumab, Benra, Fasenra

06

What researchers measure

Primary outcomes

  1. Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12

    The urticaria participant daily diary (UPDD) was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the itch severity score (ISS). The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day -1) and Week 12

Secondary outcomes

  1. LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24

    The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the UAS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day -1) and Weeks 12 and 24

  2. LS Mean Change From Baseline in ISS7 at Week 24

    The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the ISS. The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day -1) and Week 24

  3. Percentage of Responders at Weeks 12 and 24

    Responder was defined as a participant whose condition was considered clinically well controlled with UAS7 \<=6 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.

    Time frame: Weeks 12 and 24

  4. LS Mean Change From Baseline in Hives Severity Score Over 7 Days (HSS7) at Weeks 12 and 24

    The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the HSS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The HSS7 is the sum of hives severity score for the previous 7 days. The HSS7 represents hives severity on a scale from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of hives. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

    Time frame: Baseline (Day -1) and Weeks 12 and 24

  5. Time to >=5-Point Decrease in ISS7

    The time to \>=5-point decrease (clinically relevant decrease) in ISS7 was reported. The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch.

    Time frame: From Baseline (Day -1) up to Week 24

  6. Percentage of Participants With Complete UAS7 Response at Weeks 12 and 24

    Complete response was defined as participants with UAS7= 0 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.

    Time frame: Weeks 12 and 24

  7. Mean Percentage of Angioedema-Free Days Over the Past 7 Days at Weeks 12 and 24

    The UPDD included a daily yes/no question asking whether the participant experienced angioedema during the past 24 hours. If yes, the participant was asked a follow-up question about how they treated the swelling. The percentage of angioedema-free days was calculated over the past 7 days by (number of angioedema-free days/number of non-missing responses) x 100.

    Time frame: Weeks 12 and 24

  8. LS Mean Change From Baseline in Urticaria Control Test (UCT) at Weeks 12 and 24

    Urticaria disease control was assessed by the UCT using the electronic participant-reported outcome device. The UCT has a retrospective approach using a recall period of 4 weeks and responses on 5-point Likert scales with score ranging from 0 to 4 for each question. Subsequently, the scores for all 4 questions were summed up. The UCT scale range from 0 (minimum) to 16 (maximum). Higher scores indicate better disease control.

    Time frame: Baseline (Day -1) and Weeks 12 and 24

  9. LS Mean Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Weeks 12 and 24

    The CU-Q2oL is a 23-item assessment of CSU-specific health-related quality of life. Participants were asked to rate their CSU symptoms and the impact of their symptoms over the last 2 weeks on several domains: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. The questions were scored as 1= not at all, 2= a little, 3= moderately, 4= very much, 5= extremely. The scores were transformed into percentages of the maximum possible score. The CU-Q2oL scale range from 0 (minimum) to 100 (maximum). Higher scores indicate greater impact of urticaria on health-related quality of life.

    Time frame: Baseline (Day -1) and Weeks 12 and 24

  10. LS Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Weeks 12 and 24

    The DLQI is a 10-item assessment of dermatology-specific health-related quality of life. Participants were asked to rate their symptoms and the impact of their symptoms over the last week on several domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The questions (except question 7) were scored on a 4-point Likert scale: 0= not at all, 1= a little, 2= a lot, 3= very much. Scoring question 7, the first part asked: 'Over the last week, has your skin prevented you from working or studying?' Scoring was for response of 0= not relevant and 3= yes. If response was 'no', a further question was asked: 'How much has your skin been a problem at work or studying', and scored as: 0= not at all, 1= a little, 2= a lot. The DLQI was calculated by summing the score of each question. The DLQI scale range from 0 (minimum) to 30 (maximum). Higher scores indicate greater impact on participant's life.

    Time frame: Baseline (Day -1) and Weeks 12 and 24

  11. Serum Concentration of Benralizumab

    Blood samples were collected to determine the serum concentration of benralizumab.

    Time frame: Pre-dose on Weeks 4, 12 and 24

  12. Number of Participants With Anti-Drug Antibody (ADA) Response to Benralizumab

    Blood samples were measured for the presence of ADAs for benralizumab using validated assays. The ADA incidence (treatment-emergent ADA positive) was defined as ADA negative at baseline and post-baseline ADA positive, or ADA positive at baseline and boosted the pre-existing titre by \> 4-fold during the study period. Persistently positive was defined as ADA negative at baseline and positive at \>= 2 post-baseline assessments (with \>= 16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as ADA negative at baseline, having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. The median of maximum titres was calculated based on the maximum titre for each ADA positive participant within each treatment group (including both baseline and post-baseline measurements).

    Time frame: Pre-dose on Weeks 12 and 24

07

Results

Posted Mar 13, 2024
Limitations and caveats
The study was terminated early by the sponsor as the primary analysis results did not support the continued development of benralizumab for the indication of CSU.

Participant flow

This Phase 2b, randomized, double-blind study was conducted in participants with chronic spontaneous urticaria (CSU) who were symptomatic despite the use of antihistamines at 46 study centers in Bulgaria, Germany, Japan, Korea, Poland, Spain, and United States of America between 27 October 2020 and 28 March 2023. The study was terminated early by the sponsor as primary results did not support the continued development of benralizumab for the indication of CSU.

Participant flow — Overall Study
MilestoneDouble-blind Then Extension Period: Benralizumab 30 mg Q4WDouble-blind Then Extension Period: Benralizumab 30 mg Q8WDouble-blind Then Extension Period: Benralizumab 60 mg Q4WDouble-blind Then Extension Period: Benralizumab 60 mg Q8WDouble-blind Then Extension Period: Placebo
Started3029282840
Completed the treatment period2627252837
Entered extension period2426252837
Completed1621202324
Not completed1488516
Withdrew: Adverse event13101
Withdrew: Lost to follow-up01000
Withdrew: Physician decision20000
Withdrew: Study terminated by sponsor31245
Withdrew: Withdrawal by subject83519
Withdrew: Other00001

Outcome measures

PrimaryLeast Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12

The urticaria participant daily diary (UPDD) was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the itch severity score (ISS). The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day -1) and Week 12
Reported as:
Least squares mean · units on a scale
Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12-7.50 (-8.94 to -6.05)-8.28 (-9.76 to -6.80)-6.49 (-8.24 to -4.74)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.3824 (Change from baseline in ISS7 at Week 12= Treatment + baseline ISS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.01 · 95% CI -3.28 to 1.26
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.1244 (Change from baseline in ISS7 at Week 12= Treatment + baseline ISS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.79 · 95% CI -4.09 to 0.50
SecondaryLS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24

The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the UAS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day -1) and Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 12-14.48 (-17.58 to -11.38)-16.77 (-19.94 to -13.59)-12.41 (-16.17 to -8.65)
Week 24-17.99 (-21.29 to -14.68)-19.17 (-22.51 to -15.83)-15.43 (-19.43 to -11.44)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.4016 (Change from baseline in UAS7 at Week 12= Treatment + baseline UAS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -2.07 · 95% CI -6.95 to 2.80
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.0819 (Change from baseline in UAS7 at Week 12= Treatment + baseline UAS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -4.36 · 95% CI -9.28 to 0.56
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.3314 (Change from baseline in UAS7 at Week 24= Treatment + baseline UAS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -2.56 · 95% CI -7.74 to 2.63
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.1582 (Change from baseline in UAS7 at Week 24= Treatment + baseline UAS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -3.74 · 95% CI -8.95 to 1.47
SecondaryLS Mean Change From Baseline in ISS7 at Week 24

The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the ISS. The ISS represents severity on a scale ranging from 0 to 3 (where 0= none, 1= mild, 2= moderate and 3= severe). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day -1) and Week 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in ISS7 at Week 24
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
LS Mean Change From Baseline in ISS7 at Week 24-9.19 (-10.77 to -7.61)-9.33 (-10.93 to -7.73)-7.57 (-9.48 to -5.66)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.1995 (Change from baseline in ISS7 at Week 24= Treatment + baseline ISS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.62 · 95% CI -4.10 to 0.86
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.1654 (Change from baseline in ISS7 at Week 24= Treatment + baseline ISS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.76 · 95% CI -4.25 to 0.73
SecondaryPercentage of Responders at Weeks 12 and 24

Responder was defined as a participant whose condition was considered clinically well controlled with UAS7 \<=6 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.

Time frame:
Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Responders at Weeks 12 and 24
percentage of participantsBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 1222.021.410.0
Week 2428.837.527.5
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Regression, Logistic · p = 0.1373 (Week 12: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.) · Percentage difference: 11.72 · 95% CI -2.37 to 25.82
  • Benralizumab 60 mg vs Placebo · Regression, Logistic · p = 0.1697 (Week 12: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.) · Percentage difference: 10.73 · 95% CI -3.42 to 24.88
  • Benralizumab 30 mg vs Placebo · Regression, Logistic · p = 0.9105 (Week 24: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.) · Percentage difference: 1.03 · 95% CI -16.90 to 18.96
  • Benralizumab 60 mg vs Placebo · Regression, Logistic · p = 0.3389 (Week 24: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.) · Percentage difference: 9.27 · 95% CI -9.37 to 27.90
SecondaryLS Mean Change From Baseline in Hives Severity Score Over 7 Days (HSS7) at Weeks 12 and 24

The UPDD was completed twice daily (morning and evening) to capture key measures of urticaria disease activity including the HSS7. Participants were asked to document the number of hives they experienced on a scale ranging from 0 to 3 (where 0= none, 1= mild \[1 - 6 hives/12 hour\], 2= moderate \[7 - 12 hives/12 hour\] and 3= intense \[(\> 12 hives/12 hour\]). The HSS7 is the sum of hives severity score for the previous 7 days. The HSS7 represents hives severity on a scale from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of hives. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.

Time frame:
Baseline (Day -1) and Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in Hives Severity Score Over 7 Days (HSS7) at Weeks 12 and 24
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 12-7.03 (-8.84 to -5.22)-8.47 (-10.32 to -6.62)-5.87 (-8.06 to -3.68)
Week 24-8.88 (-10.76 to -7.00)-9.81 (-11.71 to -7.91)-7.82 (-10.09 to -5.54)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.4203 (Change from baseline in HSS7 at Week 12= Treatment + baseline HSS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.16 · 95% CI -4.00 to 1.68
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.0754 (Change from baseline in HSS7 at Week 12= Treatment + baseline HSS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -2.60 · 95% CI -5.46 to 0.27
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.4772 (Change from baseline in HSS7 at Week 24= Treatment + baseline HSS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.06 · 95% CI -4.01 to 1.89
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.1851 (Change from baseline in HSS7 at Week 24= Treatment + baseline HSS7 + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -2.00 · 95% CI -4.96 to 0.97
SecondaryTime to >=5-Point Decrease in ISS7

The time to \>=5-point decrease (clinically relevant decrease) in ISS7 was reported. The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch.

Time frame:
From Baseline (Day -1) up to Week 24
Reported as:
Median · weeks
Time to >=5-Point Decrease in ISS7
weeksBenralizumab 30 mgBenralizumab 60 mgPlacebo
Time to >=5-Point Decrease in ISS73.0 (2.0 to 5.0)2.0 (2.0 to 3.0)8.0 (3.0 to 11.0)
SecondaryPercentage of Participants With Complete UAS7 Response at Weeks 12 and 24

Complete response was defined as participants with UAS7= 0 at specific time points. The UAS7 is the sum of UAS for the previous 7 days, that is, the sum of ISS7 and HSS7. The UAS7 represents urticaria severity on a scale from 0 (minimum) to 42 (maximum). Higher scores indicate greater severity of urticaria symptoms.

Time frame:
Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Complete UAS7 Response at Weeks 12 and 24
percentage of participantsBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 1211.97.110.0
Week 2416.921.420.0
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Regression, Logistic · p = 0.9678 (Week 12: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.)
  • Benralizumab 60 mg vs Placebo · Regression, Logistic · p = 0.3689 (Week 12: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.)
  • Benralizumab 30 mg vs Placebo · Regression, Logistic · p = 0.6624 (Week 24: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.) · Percentage difference: -3.43 · 95% CI -18.96 to 12.11
  • Benralizumab 60 mg vs Placebo · Regression, Logistic · p = 0.9726 (Week 24: Estimates included treatment group, region (Europe, North America, Asia) and baseline UAS7.) · Percentage difference: 0.28 · 95% CI -15.84 to 16.40
SecondaryMean Percentage of Angioedema-Free Days Over the Past 7 Days at Weeks 12 and 24

The UPDD included a daily yes/no question asking whether the participant experienced angioedema during the past 24 hours. If yes, the participant was asked a follow-up question about how they treated the swelling. The percentage of angioedema-free days was calculated over the past 7 days by (number of angioedema-free days/number of non-missing responses) x 100.

Time frame:
Weeks 12 and 24
Reported as:
Mean · percentage of days
Mean Percentage of Angioedema-Free Days Over the Past 7 Days at Weeks 12 and 24
percentage of daysBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 1277.50 ± 35.99085.63 ± 32.43581.93 ± 34.548
Week 2478.50 ± 36.99291.33 ± 27.03286.79 ± 31.798
SecondaryLS Mean Change From Baseline in Urticaria Control Test (UCT) at Weeks 12 and 24

Urticaria disease control was assessed by the UCT using the electronic participant-reported outcome device. The UCT has a retrospective approach using a recall period of 4 weeks and responses on 5-point Likert scales with score ranging from 0 to 4 for each question. Subsequently, the scores for all 4 questions were summed up. The UCT scale range from 0 (minimum) to 16 (maximum). Higher scores indicate better disease control.

Time frame:
Baseline (Day -1) and Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in Urticaria Control Test (UCT) at Weeks 12 and 24
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 124.74 (3.71 to 5.76)6.11 (5.05 to 7.17)5.02 (3.78 to 6.26)
Week 245.24 (4.04 to 6.45)6.87 (5.65 to 8.09)5.88 (4.44 to 7.32)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.7256 (Change from baseline in UCT at Week 12= Treatment + baseline UCT + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -0.29 · 95% CI -1.90 to 1.32
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.1890 (Change from baseline in UCT at Week 12= Treatment + baseline UCT + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: 1.09 · 95% CI -0.54 to 2.72
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.5048 (Change from baseline in UCT at Week 24= Treatment + baseline UCT + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -0.63 · 95% CI -2.51 to 1.24
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.2991 (Change from baseline in UCT at Week 24= Treatment + baseline UCT + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: 0.99 · 95% CI -0.89 to 2.88
SecondaryLS Mean Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Weeks 12 and 24

The CU-Q2oL is a 23-item assessment of CSU-specific health-related quality of life. Participants were asked to rate their CSU symptoms and the impact of their symptoms over the last 2 weeks on several domains: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. The questions were scored as 1= not at all, 2= a little, 3= moderately, 4= very much, 5= extremely. The scores were transformed into percentages of the maximum possible score. The CU-Q2oL scale range from 0 (minimum) to 100 (maximum). Higher scores indicate greater impact of urticaria on health-related quality of life.

Time frame:
Baseline (Day -1) and Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Weeks 12 and 24
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 12-16.47 (-20.10 to -12.84)-20.34 (-24.09 to -16.60)-18.10 (-22.46 to -13.74)
Week 24-17.60 (-21.81 to -13.40)-22.11 (-26.38 to -17.84)-19.07 (-24.09 to -14.05)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.5704 (Change from baseline in CU-Q2oL at Week 12= Treatment + baseline CU-Q2oL + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: 1.63 · 95% CI -4.05 to 7.32
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.4416 (Change from baseline in CU-Q2oL at Week 12= Treatment + baseline CU-Q2oL + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -2.24 · 95% CI -7.98 to 3.50
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.6591 (Change from baseline in CU-Q2oL at Week 24= Treatment + baseline CU-Q2oL + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: 1.47 · 95% CI -5.09 to 8.02
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.3624 (Change from baseline in CU-Q2oL at Week 24= Treatment + baseline CU-Q2oL + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -3.04 · 95% CI -9.62 to 3.54
SecondaryLS Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Weeks 12 and 24

The DLQI is a 10-item assessment of dermatology-specific health-related quality of life. Participants were asked to rate their symptoms and the impact of their symptoms over the last week on several domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The questions (except question 7) were scored on a 4-point Likert scale: 0= not at all, 1= a little, 2= a lot, 3= very much. Scoring question 7, the first part asked: 'Over the last week, has your skin prevented you from working or studying?' Scoring was for response of 0= not relevant and 3= yes. If response was 'no', a further question was asked: 'How much has your skin been a problem at work or studying', and scored as: 0= not at all, 1= a little, 2= a lot. The DLQI was calculated by summing the score of each question. The DLQI scale range from 0 (minimum) to 30 (maximum). Higher scores indicate greater impact on participant's life.

Time frame:
Baseline (Day -1) and Weeks 12 and 24
Reported as:
Least squares mean · units on a scale
LS Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Weeks 12 and 24
units on a scaleBenralizumab 30 mgBenralizumab 60 mgPlacebo
Week 12-7.58 (-9.18 to -5.98)-9.31 (-10.96 to -7.66)-8.06 (-9.98 to -6.14)
Week 24-8.13 (-9.84 to -6.42)-10.25 (-11.98 to -8.51)-9.37 (-11.41 to -7.33)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.7037 (Change from baseline in DLQI at Week 12= Treatment + baseline DLQI + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: 0.48 · 95% CI -2.02 to 2.98
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.3320 (Change from baseline in DLQI at Week 12= Treatment + baseline DLQI + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -1.25 · 95% CI -3.78 to 1.29
  • Benralizumab 30 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.3590 (Change from baseline in DLQI at Week 24= Treatment + baseline DLQI + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: 1.24 · 95% CI -1.42 to 3.90
  • Benralizumab 60 mg vs Placebo · Mixed-effect model for repeated measures · p = 0.5175 (Change from baseline in DLQI at Week 24= Treatment + baseline DLQI + region (Europe, North America, Asia) + visit + treatment by visit.) · Ls mean difference: -0.88 · 95% CI -3.56 to 1.80
SecondarySerum Concentration of Benralizumab

Blood samples were collected to determine the serum concentration of benralizumab.

Time frame:
Pre-dose on Weeks 4, 12 and 24
Reported as:
Mean · nanogram per milliliter (ng/mL)
Serum Concentration of Benralizumab
nanogram per milliliter (ng/mL)Benralizumab 30 mgBenralizumab 60 mgPlacebo
Week 4990.515 ± 448.67992167.606 ± 991.7509—
Week 121321.373 ± 740.50703145.352 ± 1577.6726—
Week 241372.806 ± 883.58301638.810 ± 946.9466NA ± NA
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Benralizumab

Blood samples were measured for the presence of ADAs for benralizumab using validated assays. The ADA incidence (treatment-emergent ADA positive) was defined as ADA negative at baseline and post-baseline ADA positive, or ADA positive at baseline and boosted the pre-existing titre by \> 4-fold during the study period. Persistently positive was defined as ADA negative at baseline and positive at \>= 2 post-baseline assessments (with \>= 16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as ADA negative at baseline, having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. The median of maximum titres was calculated based on the maximum titre for each ADA positive participant within each treatment group (including both baseline and post-baseline measurements).

Time frame:
Pre-dose on Weeks 12 and 24
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Benralizumab
ParticipantsBenralizumab 30 mgBenralizumab 60 mgPlacebo
ADA prevalence18134
ADA negative (both baseline and post-baseline negative)374133
Only baseline positive110
Baseline and at least 1 post-baseline positive340
ADA incidence15104
ADA persistently positive1044
ADA transiently positive550
ADA positive with maximum titre > median of maximum titres851
ADA positive with maximum titre <= median of maximum titres1083

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are reported from the first dose administration up to 30days after the last dose of study drug, a maximum of approximately 57 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Period: Benralizumab 30 mg Q4W0/59 (0%)3/59 (5.1%)14/59 (23.7%)
Double-blind Period: Benralizumab 60 mg Q4W0/56 (0%)1/56 (1.8%)13/56 (23.2%)
Double-blind Period: Placebo0/40 (0%)0/40 (0%)10/40 (25%)
Extension Period: Benralizumab 30 mg Q4W0/49 (0%)0/49 (0%)16/49 (32.7%)
Extension Period: Benralizumab 30 mg Q8W0/54 (0%)3/54 (5.6%)12/54 (22.2%)
Extension Period: Placebo to Benralizumab0/37 (0%)1/37 (2.7%)11/37 (29.7%)
Most frequent serious events
Most frequent serious events
EventDouble-blind Period: Benralizumab 30 mg Q4WDouble-blind Period: Benralizumab 60 mg Q4WDouble-blind Period: PlaceboExtension Period: Benralizumab 30 mg Q4WExtension Period: Benralizumab 30 mg Q8WExtension Period: Placebo to Benralizumab
AsthmaRespiratory, thoracic and mediastinal disorders0/590/560/400/490/541/37
UreterolithiasisRenal and urinary disorders0/590/560/400/491/540/37
Meniscus injuryInjury, poisoning and procedural complications0/590/560/400/491/540/37
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/590/560/400/491/540/37
UrticariaSkin and subcutaneous tissue disorders0/591/560/400/490/540/37
Biliary colicHepatobiliary disorders1/590/560/400/490/540/37
HypersensitivityImmune system disorders1/590/560/400/490/540/37
Subarachnoid haemorrhageNervous system disorders1/590/560/400/490/540/37
Most frequent other events
Most frequent other events
EventDouble-blind Period: Benralizumab 30 mg Q4WDouble-blind Period: Benralizumab 60 mg Q4WDouble-blind Period: PlaceboExtension Period: Benralizumab 30 mg Q4WExtension Period: Benralizumab 30 mg Q8WExtension Period: Placebo to Benralizumab
COVID-19Infections and infestations5/595/561/404/494/545/37
NasopharyngitisInfections and infestations1/594/562/405/492/542/37
SinusitisInfections and infestations2/590/561/401/490/543/37
ArthralgiaMusculoskeletal and connective tissue disorders2/590/562/400/491/543/37
Ligament sprainInjury, poisoning and procedural complications0/590/561/403/491/540/37
Back painMusculoskeletal and connective tissue disorders0/592/561/402/493/540/37
HeadacheNervous system disorders3/593/562/402/491/541/37
MyalgiaMusculoskeletal and connective tissue disorders3/591/561/401/490/540/37

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug, irrespective of their protocol adherence and continued participation in the study.

Age, Customized
Age, Customized(Participants)Benralizumab 30 mgBenralizumab 60 mgPlaceboTotal
<35 years1115834
>=35 to <=55 years32252279
>55 years16161042
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mgBenralizumab 60 mgPlaceboTotal
Female444525114
Male15111541
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab 30 mgBenralizumab 60 mgPlaceboTotal
White464230118
Asian1212832
Black or African American1203
Not reported0022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benralizumab 30 mgBenralizumab 60 mgPlaceboTotal
Hispanic or Latino24410
Not Hispanic or Latino575236145
08

Study locations

40 sites
  • Research Site
    Scottsdale, Arizona 85260, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Cincinnati, Ohio 45229, United States
  • Research Site
    Cincinnati, Ohio 45236, United States
  • Research Site
    Norman, Oklahoma 73071, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    Haskovo, 6300, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Ruse, 7013, Bulgaria
  • Research Site
    Sofia, 1000, Bulgaria
  • Research Site
    Sofia, 1463, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Sofia, 1680, Bulgaria
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Hiroshima-shi, 734-8551, Japan
  • Research Site
    Kamimashikigun,, 861-3106, Japan
  • Research Site
    Kawasaki-shi, 211-0063, Japan
  • Research Site
    Kobe-shi, 650-0017, Japan
  • Research Site
    Sakai-shi, 593-8324, Japan
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06973, Korea, Republic of
  • Research Site
    Seoul, 6591, Korea, Republic of
  • Research Site
    Gdańsk, 80-546, Poland
  • Research Site
    Krakow, 30-033, Poland
  • Research Site
    Poznań, 60-214, Poland
  • Research Site
    Warszawa, 02-507, Poland
  • Research Site
    Wrocław, 50-449, Poland
  • Research Site
    Alicante, 03010, Spain
  • Research Site
    Barcelona, 8003, Spain
  • Research Site
    Cordoba, 14004, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Manises, 46940, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Oct 2022, 23 months.

Results were first posted in Mar 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Nov 3, 2020
StartActual
Oct 27, 2020
Primary completionActual
Oct 13, 2022
CompletionActual
Mar 28, 2023
Results first posted
Mar 13, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04612725
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Nov 3, 2020
Start date
Oct 27, 2020
Primary completion
Oct 13, 2022
Completion
Mar 28, 2023
Results posted
Mar 13, 2024
Last update
Mar 13, 2024

Study contacts

Sabine Altrichter, MD
principal investigator · Charite Universitaetsmedizin Berlin - Campus Charite Mitte

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion